延安必康(002411.SZ)與圖微安創簽署戰略合作協議
格隆匯2月6日丨延安必康(002411.SZ)公佈，公司(“甲方”)近日與深圳市圖微安創科技開發有限公司(“圖微安創”、“乙方”)簽署《戰略合作協議》。經友好協商決定建立緊密的戰略合作伙伴關係，雙方經協商一致，達成戰略合作協議。
圖微安創是一家從事1.1類創新藥物研發的高新技術企業，主要聚焦於開發治療組織器官纖維化的多肽藥物。
目前新型冠狀病毒(2019-nCoV)的治療手段主要集中於抗病毒和抗炎，對重症患者也綜合採用了提高肺功能的治療手段。然而對於患者進行性伴隨肺纖維化的臨牀表現肺纖維化導致的呼吸衰竭也是導致死亡的最主要原因，目前根本無有效藥物治療。從以往SARS和MERS患者臨牀顯示SARS和MERS所致的肺纖維化是這類新型冠狀病毒疾病的一個重要特點，不但是該病發病中的重要臨牀表現之一，而且是病人恢復後一個常見的後遺症，嚴重影響病人的生活質量和預後。
圖微安創目前已經開發出了對肺纖維化具有良好的治療逆轉作用的多肽藥物，經臨牀前研究結果顯示：在多個肺纖維化動物模型上治療性逆轉肺纖維化面積，及相關的生物指標逆轉在80%以上，屬於全球首創；而且用藥劑量小、無明顯毒副作用；該多肽藥物正處於正式的臨牀前研究IND階段，未來有望成為治療肺纖維化領域的明星藥物。
圖微安創設計並研發了基於EDPs靶點的抗肺纖維化1.1類多肽藥物TB-B002，該藥物在應對當下新型冠狀病毒肺炎患者的治療以及未來出院病人進一步的康復治療具有重要臨牀價值。
此次協議的主要內容為：1、雙方在合作中建立以互信、慣例與默契為基礎的合作伙伴關係，充分發揮雙方優勢、提高競爭力，共同進行市場開拓。2、甲方將在乙方的治療肺纖維化藥物申報方面，協助乙方獲得相應的綠色通道加快臨牀試驗；並在乙方的其他藥物申報註冊方面，應乙方的請求也可以提供相應的支持和幫助。3、乙方將視其藥物開發進度，經與股東/投資人的協調，可接受甲方的投資。4、乙方在未來還可根據藥物開發進度，與甲方合作生產核准註冊的藥物。
公司與圖微安創基於充分發揮雙方優勢的基礎上，建立緊密的戰略合作伙伴關係，有利於加快公司戰略佈局的實現，提升公司醫藥製造產能的綜合利用率，提高公司盈利水平和市場競爭力，促進公司持續、健康、穩步發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
